How Have Bristol-Myers Squibb’s Revenues, Expenses & Profits Changed Over The Last Five Years?
We have created an interactive dashboard which looks at how Bristol-Myers Squibb’s (NYSE:BMY) revenues, expenses, and profits have changed over the last five years, as well as our forecasts for 2018. You can adjust the expected segment-wise revenue and margin forecast for 2018, and see its impact on the profitability, and earnings.
- The overall revenues increased by $4 billion over the last five years. This can be attributed to a significant ramp up in oncology drugs and cardiovascular drugs sales.
Change In Operating Expenses By Division Between 2013 and 2017
- Operating expenses have increased by $1.6 billion over the last five years. This can be attributed to the oncology and cardiovascular segments, which saw an uptick in revenues during the period.
- Should You Pick Bristol Myers Squibb Stock After A 30% Fall Last Year And Q4 Beat?
- Is Bristol Myers Squibb Stock Undervalued At $50?
- Will Bristol Myers Squibb Stock Rebound To Its Pre-Inflation Shock Level of $80?
- Which Stock Is A Better Healthcare Pick – Bristol Myers Squibb Or HCA?
- Will Bristol Myers Squibb Stock Rise Post Q1?
- Is Bristol Myers Squibb Stock A Better Pick Over Its Industry Peer?
- The gross profit for the company increased by $2.8 billion over the last five years, led by oncology and cardiovascular drugs.
- We forecast BMY’s oncology drugs sales to grow in 2018 to around $9.3 billion led by a ramp up in Opdivo sales.
- We also expect BMY’s Eliquis (in the cardiovascular segment) to continue to grow in the near term, as it is gaining market share. We estimate the segment sales to be around $5.2 billion in 2018.
Expect 2018 EPS To Be $3.2
- We currently estimate the company’s EPS in 2018 to be $3.19, and our current price estimate for BMY is $60. You can adjust the Net Income to Gross Profit Ratio to arrive at your EPS estimate.
Our price estimate of $60 for Bristol Myers Squibb implies a discount of over 10% to the market.
What’s behind Trefis? See How it’s Powering New Collaboration and What-Ifs
For CFOs and Finance Teams | Product, R&D, and Marketing Teams
Like our charts? Explore example interactive dashboards and create your own